文献速递乳腺癌

WSG ADAPT试验中预测短期术前内分泌治疗反应临床与分子标志物

Clinical and molecular biomarkers for prediction of endocrine response after short preoperative endocrine therapy in the WSG ADAPT-HR+/HER2- and ADAPTcycle trials (N = 7914).
PubMed 文献 · Ann Oncol · 2026-04-16

在WSG ADAPT-HR+/HER2-和ADAPTcycle两项III期试验中,分析7914例HR+/HER2-早期乳腺癌患者短期术前内分泌治疗后Ki67≤10%的预测因素。AI治疗的反应率高于他莫昔芬,绝经前加OFS可提高反应率;AI使用、年龄>50岁、较低RS和基线Ki67、较高ER和HER2表达为预测因素,内分泌反应联合基因表达评估有助于避免化疗。

要点

  • AI的反应率高于他莫昔芬,绝经前加OFS可达到与绝经后相似的反应率
  • 预测因素包括AI使用、年龄>50岁、较低RS和基线Ki67、较高ER和HER2表达
  • 内分泌反应联合基因表达评估可帮助luminal早期乳腺癌患者避免化疗

核心结论

  • 两项大型III期试验中内分泌治疗反应率相似,绝经后患者(多接受AI)反应率高于年轻患者。
  • 年轻患者使用GnRH+AI的反应率与绝经后患者相当,提示差异源于治疗而非生物学。
  • 联合内分泌反应与基因表达评估可能帮助更多luminal早期乳腺癌患者避免化疗。

研究设计与样本

  • ADAPT-HR+/HER2-中≤50岁且绝经前1250例,>50岁或绝经后2425例;ADAPTcycle中≤50岁1336例,>50岁2903例。
  • 通过多变量逻辑回归模型识别内分泌治疗反应的预测因素。

主要发现

  • ADAPT-HR+/HER2-和ADAPTcycle中AI的反应率分别为81.4%和76.7%,他莫昔芬为40.1%和34.7%。
  • 绝经前患者GnRH+AI的反应率与绝经后患者相似。
  • 预测因素包括AI使用(绝经前加OFS)、年龄>50岁、较低RS和基线Ki67、较高ER(免疫组化)和HER2(Oncotype DX)表达。
  • ADAPT-HR+/HER2-中内分泌反应者的5年无远处病生存率明显高于无反应者,也高于化疗治疗的N0-1且RS>25患者(87.0% vs 80.7%)。

关键数值与推荐

  • 内分泌治疗反应定义为2-4周标准内分泌治疗后Ki67≤10%。
  • ADAPT-HR+/HER2-中高临床风险N0-1且RS 0-11或RS 12-25且内分泌反应者接受单纯内分泌治疗。

临床怎么用

  • 短期术前内分泌治疗后检测Ki67可评估内分泌反应,指导治疗降阶。
  • 绝经前患者使用GnRH+AI可提高内分泌反应率,达到与绝经后相似的水平。
  • 结合内分泌反应与基因表达评估(如RS)有助于筛选可避免化疗的luminal早期乳腺癌患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Low Ki67 after short preoperative endocrine therapy (ET) indicates a favorable prognosis in hormone receptor-positive/human epidermal growth factor receptor 2 (HER2)-negative early breast cancer (eBC). We investigated predictors of ET response in the West German Study Group (WSG) ADAPT-HR+/HER2- and ADAPTcycle trials. PATIENTS AND METHODS: ET response (Ki67 ≤10%) after 2- to 4-week standard ET, recurrence score (RS), and nodal status were used for treatment allocation. In ADAPT-HR+/HER2-, patients at high clinical risk received ET alone if N0-1 and RS 0-11 or RS 12-25 and ET response. In ADAPTcycle, N0-1 patients with RS > 25 and ET response and those with RS < 25 and e.g. ET nonresponse, N2-3 patients with RS ≤ 25 and ET response, were randomly assigned to receive (neo)adjuvant chemotherapy or aromatase inhibitor (AI)+ribociclib. Predictors of ET response were identified through multivariable logistic regression models. RESULTS: Three thousand six hundred seventy-five patients from the ADAPT-HR+/HER2- cohort (≤50 years and premenopausal, ≤50 years: N = 1250; >50 years or postmenopausal, >50 years: N = 2425) and 4239 from the ADAPTcycle screening cohort (≤50 years: N = 1336; >50 years: N = 2903) were analyzed. ET response rates were higher after AI (ADAPT-HR+/HER2-/ADAPTcycle: 81.4%/76.7%) versus tamoxifen (ADAPT-HR+/HER2-/ADAPTcycle: 40.1%/34.7%) in both age groups, with further improvement by ovarian function suppression (OFS) in premenopausal patients. Premenopausal patients with GnRH plus AI had similar ET response rates as postmenopausal patients. ET response predictors included AI use (plus OFS in premenopausal), age >50 years, lower RS and baseline Ki67 levels, and higher expression of estrogen receptor (by immunohistochemistry) and HER2 (by Oncotype DX™). In ADAPT-HR+/HER2-, 5-year distant disease-free survival in ET responders was markedly higher than in nonresponders and also in chemotherapy-treated N0-1 patients with RS > 25 (87.0 versus 80.7%), and it was only slightly lower than that in the RS 12-25 group. CONCLUSIONS: We observed similar ET response rates in two large phase III trials. Postmenopausal patients (mostly receiving AI) had higher ET response rates than younger patients. However, young patients with GnRH+AI had ET response rates comparable with those of postmenopausal patients, suggesting that therapy rather than biology accounts for the difference. Combining ET response and gene expression assessment could help more patients with luminal eBC avoid chemotherapy.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Gluz O, Nitz U, Christgen M, et al. Clinical and molecular biomarkers for prediction of endocrine response after short preoperative endocrine therapy in the WSG ADAPT-HR+/HER2- and ADAPTcycle trials (N = 7914). Ann Oncol. 2026. PMID: 41999978. doi:10.1016/j.annonc.2026.04.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。